

Ulrik S Srensen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3796733/ulrik-s-sorensen-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

13
papers

407
citations

8
h-index

13
g-index

13
ext. papers

470
ext. citations

5.2
avg, IF

2.89
L-index

#	Paper	IF	Citations
13	Inhibition of small-conductance Ca ²⁺ -activated K ⁺ channels terminates and protects against atrial fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2010 , 3, 380-90	6.4	135
12	Inhibitory gating modulation of small conductance Ca ²⁺ -activated K ⁺ channels by the synthetic compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) reduces afterhyperpolarizing current in hippocampal CA1 neurons. <i>Molecular Pharmacology</i> , 2006 , 70, 1771-82	4.3	90
11	Synthesis and structure-activity relationship studies of 2-(N-substituted)-aminobenzimidazoles as potent negative gating modulators of small conductance Ca ²⁺ -activated K ⁺ channels. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 7625-34	8.3	56
10	Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca) ₂ channels. <i>Molecular Pharmacology</i> , 2011 , 79, 899-909	4.3	40
9	Role of Calcium-activated Potassium Channels in Atrial Fibrillation Pathophysiology and Therapy. <i>Journal of Cardiovascular Pharmacology</i> , 2015 , 66, 441-8	3.1	29
8	A new negative allosteric modulator, AP14145, for the study of small conductance calcium-activated potassium (K ₂) channels. <i>British Journal of Pharmacology</i> , 2017 , 174, 4396-4408	8.6	17
7	The K ₂ Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs. <i>Frontiers in Pharmacology</i> , 2020 , 11, 159	5.6	13
6	Arrhythmia development during inhibition of small-conductance calcium-activated potassium channels in acute myocardial infarction in a porcine model. <i>Europace</i> , 2019 , 21, 1584-1593	3.9	9
5	The K ₂ Channel Inhibitor AP14145, But Not Dofetilide or Ondansetron, Provides Functional Atrial Selectivity in Guinea Pig Hearts. <i>Frontiers in Pharmacology</i> , 2019 , 10, 668	5.6	8
4	Mechanisms of Action of the KCa ₂ -Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man. <i>Frontiers in Pharmacology</i> , 2020 , 11, 610	5.6	6
3	2,6-Bis(2-Benzimidazolyl)Pyridine (BBP) Is a Potent and Selective Inhibitor of Small Conductance Calcium-Activated Potassium (SK) Channels. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1409	5.6	2
2	Effective termination of atrial fibrillation by SK channel inhibition is associated with a sudden organization of fibrillatory conduction. <i>Europace</i> , 2021 , 23, 1847-1859	3.9	1
1	Inhibition of Small-Conductance Calcium-Activated Potassium Current (I _{SK}) Leads to Differential Atrial Electrophysiological Effects in a Horse Model of Persistent Atrial Fibrillation. <i>Frontiers in Physiology</i> , 2021 , 12, 614483	4.6	1